

AMENDMENTS TO THE CLAIMS

1 (Currently Amended). An isolated ~~KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5 or KLK-L6~~ nucleic acid molecule of at least 30 nucleotides which hybridizes to SEQ ID NO: ~~1, 13, 21, 43, 56, or 65, respectively,~~ or the complement of SEQ ID NO: ~~1, 13, 21, 43, 56, or 65,~~ under stringent hybridization conditions.

Claims 2-31 (CANCELED).

C 32 (Currently Amended). The isolated nucleic acid molecule according to claim 1 which comprises:

(i) a nucleic acid sequence encoding a protein having substantial sequence identity with an amino acid sequence of a ~~KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6~~ protein as shown in SEQ ID NO: ~~2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;~~

(ii) a nucleic acid sequence encoding a protein comprising an amino acid sequence of a ~~KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6~~ protein as shown in SEQ ID NO: ~~2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;~~

(iii) nucleic acid sequences complementary to (i);

(iv) a degenerate form of a nucleic acid sequence of (i);

(v) a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid sequence in (i), (ii) or (iii);

(vi) a nucleic acid sequence encoding a truncation, an analog, an allelic or species variation of a protein comprising an amino acid sequence of a ~~KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6~~ protein as shown in SEQ ID NO: ~~2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;~~ or

(vii) a fragment, or allelic or species variation of (i), (ii) or (iii).

33 (Currently Amended). The isolated nucleic acid molecule according to claim 1 which comprises:

- (i) a nucleic acid sequence comprising the sequence of SEQ ID NO: ~~1, 13, 21, 43, 56, or 65~~ wherein T can also be U;
- (ii) nucleic acid sequences complementary to (i), preferably complementary to the full nucleic acid sequence of SEQ ID NO: ~~1, 13, 21, 43, 56, or 65~~;
- (iii) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid of (i) or (ii) and preferably having at least 18 nucleotides; or
- (iv) a nucleic acid molecule differing from any of the nucleic acids of (i) to (iii) in codon sequences due to the degeneracy of the genetic code.

Claim 34 (CANCELED).

C 35(Previously Added). A vector comprising a nucleic acid molecule of claim 32.

36(Previously Added). A host cell comprising a nucleic acid molecule of claim 32.

37(Currently Amended). A method for preparing a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ~~2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, and 67~~ comprising:

- (a) transferring a vector of claim 35 into a host cell;
- (b) selecting transformed host cells from untransformed host cells;
- (c) culturing a selected transformed host cell under conditions which allow expression of the protein; and
- (d) isolating the protein.

Claim 38 (CANCELED).

39(Currently Amended). A probe comprising a sequence encoding a protein of claim 8 32 or a part thereof.

Claims 40-43 (CANCELED).

44(Currently Amended). A composition comprising a compound selected from the group consisting of:

- (a) a nucleic acid molecule of claim 1;
- (b) a protein encoded by (a) of claim 8; or
- (~~bc~~) a substance or ~~compound~~ compound identified by the method of ~~one of claims~~ claim 37 41 or 42,

said composition further comprising a pharmaceutically acceptable carrier, excipient or diluent.

Claim 45 (CANCELED).

46(New). The isolated nucleic acid sequence comprising the nucleic acid sequence of Fig. 7 that encodes ~~KLK-L2~~ protein SEQ ID NO: 14.